Genflow Biosciences plc (LSE: GENF)
Health Care · Biotechnology · GB
£0.02
-1.41% today · -18.6% 1Y
Genflow Biosciences plc (LSE: GENF) operates in the Biotechnology industry within the Health Care sector. The company is valued at $13.22M and employs 5 people.
Over the last twelve months the share price has lost 18.6%, trading between 0.01 and 0.03.
Tweenvest scores Genflow Biosciences plc across four factors: quality 35/100, value 75/100. Its strongest factor is value.
GENF price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $13.22M
- Revenue (TTM)
- $776.98K
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- 2.26
- 52-week high
- £0.03
- 52-week low
- £0.01
- Avg volume (3M)
- —
- Shares outstanding
- 566.41M
- Employees
- 5
- Next earnings
- —
About Genflow Biosciences plc
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducing the incidence of age-related diseases. Its lead drug candidate is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-1003, a topical delivery of SIRT6 to the fibroblasts in the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005, which addresses mitochondrial dysfunction observed in sarcopenia for muscle health and combat sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. The company has collaborative research agreements with Revatis SA and EXO Biologics for therapy medicinal products. Genflow Biosciences plc was founded in 2020 and is headquartered in London, the United Kingdom.
- ISIN
- GB00BP2C3V08
- Founded
- 2020
- Listed since
- Jan 18, 2022
- Exchange
- London Stock Exchange
- Currency
- GBP
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Pasithea Therapeutics Corp.NasdaqCM: KTTA | $14.03M | $0.42 | -10.16% |
| Xintela AB (publ)OM: XINT | $14.00M | Skr0.16 | -10.31% |
| BioCardia, Inc.NasdaqCM: BCDA | $13.93M | $0.92 | -11.53% |
| Biophytis S.A.ENXTPA: ALBPS | $13.57M | €0.03 | +8.81% |
| Alzinova AB (publ)OM: ALZ | $13.21M | Skr0.43 | -1.96% |
| Genomed Spólka AkcyjnaWSE: GEN | $13.14M | zł38.60 | -3.50% |
| Imugene LimitedASX: IMU | $13.09M | AU$0.04 | -2.56% |
| TME Pharma N.V.ENXTPA: ALTME | $13.07M | €0.12 | +12.32% |
Figures last refreshed Oct 18, 2026.